Proteopedia

MK-2048: Difference between revisions

← Older edit
David Canner (talk | contribs)
7,699 edits
No edit summary
David Canner (talk | contribs)
7,699 edits
No edit summary
 
(One intermediate revision by the same user not shown)
Line 7: Line 7:
* Projected Sales: N/A
* Projected Sales: N/A
* Importance: It is a second generation [[Retroviral Integrase]] inhibitor expected to be the next effective HIV treatment to come to market.  Clinical trials reveal that it is superior to [[Raltegravir]] with a nearly 4 times longer inhibition period.  
* Importance: It is a second generation [[Retroviral Integrase]] inhibitor expected to be the next effective HIV treatment to come to market.  Clinical trials reveal that it is superior to [[Raltegravir]] with a nearly 4 times longer inhibition period.  
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders.


===Mechanism of Action===
===Mechanism of Action===
Line 13: Line 13:


===Pharmacokinetics===
===Pharmacokinetics===
{| class="wikitable" border="1" width="60%" style="text-align:center"
<table style="background: cellspacing="0px"  align="" cellpadding="0px" width="50%">
|-
<tr>
!  colspan="4" align="center"| Retroviral Integrase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>A Gaur, et al. Pharmacokinetics and Safety of Once-Daily Elvitegravir in HIV-Infected Adolescents. 17th Conference on Retroviruses. Poster Number: 874.</ref><ref>doi: 10.1128/AAC.01543-07</ref>
<td style="width:auto; vertical-align:top;border-width:0px; border-style:inset">
|-
<div style="height:100%; width: 100%">
! Parameter
{{:Retroviral Integrase Inhibitor Pharmacokinetics}}
! [[Raltegravir]]
</div>
! [[Elvitegravir]]
</td>
! [[MK-2048]]
</tr>
|-
</table>
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
! 1.8
! 2-4
! N/A
|-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
! 4253
! 2070
! N/A
|-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! 32
! ~30
! N/A
|-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
! 83
! N/A
! N/A
|-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 10.8
! 7.6
! N/A
|-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! 10168
! 21200
! N/A
|-
! Dosage (mg)
! 400
! 150
! N/A
|-
! Metabolism
! Hepatic - (UGT1A1)
! Hepatic - (CYP3A4)
! N/A
|}


===References===
===References===

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner
Retrieved from "https://proteopedia.openfox.io/w/MK-2048"